Scholarlink

<p>Hypertension remains a leading global cause of cardiovascular morbidity and mortality, yet blood pressure control rates remain suboptimal despite advances in antihypertensive therapy. Multiple barriers—including cost, side effects, therapeutic complexity, and physician inertia—impede effective management, particularly in aging populations and low-resource settings. This review evaluates the therapeutic role of doxazosin, particularly in its extended-release gastrointestinal therapeutic system formulation, as a potential adjunct in contemporary hypertension treatment, including resistant hypertension.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Doxazosin GITS (gastrointestinal therapeutic system) is an actor to consider in the control of hypertension. A narrative review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月5日

查看全文
  • Miguel Camafort,
  • Hae-Young Lee,
  • Hung-Yu Chang,
  • Bancha Satirapoj,
  • Kazuomi Kario

摘要

Hypertension remains a leading global cause of cardiovascular morbidity and mortality, yet blood pressure control rates remain suboptimal despite advances in antihypertensive therapy. Multiple barriers—including cost, side effects, therapeutic complexity, and physician inertia—impede effective management, particularly in aging populations and low-resource settings. This review evaluates the therapeutic role of doxazosin, particularly in its extended-release gastrointestinal therapeutic system formulation, as a potential adjunct in contemporary hypertension treatment, including resistant hypertension.